| Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders S Mader, V Gredler, K Schanda, K Rostasy, I Dujmovic, K Pfaller, ... Journal of neuroinflammation 8, 1-14, 2011 | 490 | 2011 |
| EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-γ and IL-2 JD Lünemann, I Jelčić, S Roberts, A Lutterotti, B Tackenberg, R Martin, ... The Journal of experimental medicine 205 (8), 1763-1773, 2008 | 349 | 2008 |
| Antigen-specific tolerance by autologous myelin peptide–coupled cells: a phase 1 trial in multiple sclerosis A Lutterotti, S Yousef, A Sputtek, KH Stürner, JP Stellmann, P Breiden, ... Science translational medicine 5 (188), 188ra75-188ra75, 2013 | 335 | 2013 |
| Smoking is a risk factor for early conversion to clinically definite multiple sclerosis F Di Pauli, M Reindl, R Ehling, F Schautzer, C Gneiss, A Lutterotti, ... Multiple Sclerosis Journal 14 (8), 1026-1030, 2008 | 198 | 2008 |
| Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica S Mader, A Lutterotti, F Di Pauli, B Kuenz, K Schanda, F Aboul-Enein, ... PloS one 5 (5), e10455, 2010 | 184 | 2010 |
| Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis B Kuenz, A Lutterotti, R Ehling, C Gneiss, M Haemmerle, C Rainer, ... PloS one 3 (7), e2559, 2008 | 149 | 2008 |
| Getting specific: monoclonal antibodies in multiple sclerosis A Lutterotti, R Martin The Lancet Neurology 7 (6), 538-547, 2008 | 113 | 2008 |
| Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders M Reindl, S Khantane, R Ehling, K Schanda, A Lutterotti, C Brinkhoff, ... Journal of neuroimmunology 145 (1-2), 139-147, 2003 | 102 | 2003 |
| Olfactory threshold is impaired in early, active multiple sclerosis A Lutterotti, M Vedovello, M Reindl, R Ehling, F DiPauli, B Kuenz, ... Multiple Sclerosis Journal 17 (8), 964-969, 2011 | 93 | 2011 |
| Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis R Ehling, A Lutterotti, J Wanschitz, M Khalil, C Gneiss, F Deisenhammer, ... Multiple Sclerosis Journal 10 (6), 601-606, 2004 | 90 | 2004 |
| A new paraclinical CSF marker for hypoxia‐like tissue damage in multiple sclerosis lesions H Lassmann, M Reindl, H Rauschka, J Berger, F Aboul‐Enein, T Berger, ... Brain 126 (6), 1347-1357, 2003 | 73 | 2003 |
| Mutations in the gene for toll‐like receptor 4 and multiple sclerosis M Reindl, A Lutterotti, J Ingram, K Schanda, C Gassner, F Deisenhammer, ... Tissue Antigens 61 (1), 85-88, 2003 | 70 | 2003 |
| Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis B Kuenz, A Lutterotti, M Khalil, R Ehling, C Gneiss, F Deisenhammer, ... Journal of neuroimmunology 167 (1-2), 143-149, 2005 | 68 | 2005 |
| Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity C Gneiss, M Reindl, A Lutterotti, R Ehling, R Egg, M Khalil, T Berger, ... Multiple Sclerosis Journal 10 (5), 507-510, 2004 | 68 | 2004 |
| Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people F Aboul-Enein, T Seifert-Held, S Mader, B Kuenz, A Lutterotti, H Rauschka, ... PLoS One 8 (11), e79649, 2013 | 63 | 2013 |
| Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients C Gneiss, P Tripp, F Reichartseder, R Egg, R Ehling, A Lutterotti, M Khalil, ... Multiple Sclerosis Journal 12 (6), 731-737, 2006 | 59 | 2006 |
| Biological markers for multiple sclerosis A Lutterotti, T Berger, M Reindl Current medicinal chemistry 14 (18), 1956-1965, 2007 | 52 | 2007 |
| Antigen-specific tolerization approaches in multiple sclerosis A Lutterotti, R Martin Expert opinion on investigational drugs 23 (1), 9-20, 2014 | 47 | 2014 |
| Persistency of neutralizing antibodies depends on titer and interferon-beta preparation H Hegen, M Schleiser, C Gneiss, F Di Pauli, R Ehling, B Kuenz, ... Multiple Sclerosis Journal 18 (5), 610-615, 2012 | 46 | 2012 |
| Natalizumab treatment reduces endothelial activity in MS patients A Millonig, H Hegen, F Di Pauli, R Ehling, C Gneiss, M Hoelzl, B Künz, ... Journal of neuroimmunology 227 (1-2), 190-194, 2010 | 42 | 2010 |
